Keyword: Hikma Pharmaceuticals
Hikma has already cut 200 jobs since picking up generics business Roxane Labs from Boehringer Ingelheim. But more layoffs are coming.
GlaxoSmithKline just keeps racking up the victories in the generic Advair department, this time with a yearslong delay to Hikma's copy.
Former Teva Generics CEO Siggi Olafsson is back in the copycat game—this time, as the new CEO of Jordan’s Hikma Pharmaceuticals.
Those waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile.
Hikma's U.S. unit West-Ward boosted prices as much as fourfold on a half-dozen generic meds, most of them liquid formulations.
The FDA has already nixed two generics of GSK's Advair. But Novartis’ Sandoz is hoping its version can be the one to turn the tide.
GlaxoSmithKline dodged yet another generic Advair bullet. Hikma and Vectura's knockoff was struck down at FDA Thursday, and an approval later this year is a long shot, the companies say.
Pfizer, drug wholesaling giant McKesson, and others are trying to keep Arkansas from using their drugs in its effort to perform seven executions in short order.
Mylan execs were confident of a generic Advair approval just weeks ago, but on Wednesday got a "no-go" from the FDA. Now the question is how much it'll hurt.
Thanks to some crafty payer negotiating from GSK, even if Advair generics win approval, it may be a while before they gain serious traction, even if it wins approval on time.